Broad spectrum fluoroquinolone antibiotic suitable for treatment of gram-positive and gram-negative bacterial infections
Garenoxacin is a broad spectrum fluoroquinolone antibiotic suitable for treatment of gram-positive and gram-negative bacterial infections. Garenoxacin has a low mutant prevention concentration and a narrow mutant selection window. Data shows that garenoxacin has anti-inflammatory properties. It significantly alleviates LPS-induced IL-8 production through the negative regulation of the ERK1/2 pathway both in the human airway epithelial cell line A549 and the monocyte cell line THP-1.